_____________________________________________________________________________________________________ *Corresponding author: E-mail: arulamutha@bharathuniv.ac.in; Journal of Pharmaceutical Research International 33(21A): 41-49, 2021; Article no.JPRI.66780 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759) Comparison of Efficacy and Safety of Atorvastatin Versus Combination of Atorvastatin - Ezetimibe in Newly Diagnosed Dyslipedemic Patients Sanitha Philip 1 and Arul Amutha Elizabeth 1* 1 Department of Pharmacology, Sree Balaji Medical College and Hospital Affiliated to Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India. Authors’ contributions This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript. Article Information DOI: 10.9734/JPRI/2021/v33i21A31367 Editor(s): (1) Dr. Giuseppe Murdaca, University of Genoa, Italy. Reviewers: (1) Li Yao, Zhejiang Chinese Medical University, China. (2) Hayrullah Yazar, Sakarya University, Turkey. Complete Peer review History: http://www.sdiarticle4.com/review-history/66780 Received 24 January 2021 Accepted 31 March 2021 Published 07 April 2021 ABSTRACT Hypercholesterolemia is a major risk factor for cardiovascular disease. Low-density lipoprotein cholesterol is an established risk factor for atherosclerotic disease, particularly coronary artery disease (CAD); therefore, management of high serum LDL-C levels is the most important goal in the treatment of dyslipidemia. Since therapy with statins alone fails to achieve the targeted LDL-C values with lesser side effects it is better to try a combination therapy having high efficacy and safety profile. This study compared the efficacy and safety of the combination of Atorvastatin 10 mg +Ezetimibe 10 mg versus Atorvastatin 10 mg alone in lowering LDL-C in newly diagnosed dyslipidemic patients. Besides, it compared the efficacy of the two drugs in lowering the TC, TG, and TC/HDL-C and LDL/HDL-C ratio. We also compared the increase in HDL-C in the two groups at the end of 12 weeks. This study was conducted on 60 hypercholesterolemic patients in SreeBalaji Medical College Hospital. The patients were randomly divided into two groups of 30each. Group 1 was given Atorvastatin 10 mg +Ezetimibe 10 mg while Group 2 was given Atorvastatin 10 mg. The Lipid Profile, biochemical and hematological tests, clinical examination were done on Day 0, 6th week, and 12th week and these results were compared the group and Original Research Article